Jeil Pharma Holdings: Q1 2026 Results, Dividend Increase, and Share Buyback Plan
- Consolidated Q1 2026: Revenue 150.4B KRW, Operating Profit 3.6B KRW, Net Income (controlling) 1.1B KRW (YoY decrease)
- Dividend per share raised to 70 won (from 50 won, +40%), total dividend 1.1B KRW
- On 2026.03.13, board approved a short-term plan for treasury share acquisition/disposal/cancellation (specific amounts undisclosed)
- Net debt ratio improved to 72.7% (from 74.9% at year-end)
- One pending lawsuit (claim amount 2.77B KRW, partial provision)
- Subsidiary Onconic Therapeutics maintains tech export deals for Zastaprazan (JP-1366) to China, India, and Latin America
ADVERTISEMENT (250px+)
KOSPI Filing Information
- Filing: Quarterly Report (2026.03)
- Company: JEIL PHARMA HOLDINGS (002620)
- Submission: JEIL PHARMA HOLDINGS INC.
- Receipt: 05-15-2026